This site is intended for healthcare professionals
Photo of Prostate cancer cells under microscope, pink and purple tones.
Prostate Cancer Nexus

Ken Herrmann

Last updated: 15th Sep 2025
Published: 15th Sep 2025


Ken Herrmann, MD, MBAKen Herrmann, MD, MBA

Ken Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Germany. Herrmann is Section Editor of The Journal of Nuclear Medicine and Imaging Editor of European Urology.

Disclosures: Honoraria and/or fees from AdvanCell, Aktis Oncology, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent Therapeutics, Curium Pharma, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, MSD, Molecular Partners, Novartis (Advanced Accelerator Applications), NVision, Pfizer, Pentixapharm, POINT Biopharma, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, SOFIE Biosciences, Telix, Theragnostics, and Y-mAbs Therapeutics.

View content featuring Herrmann:

Expert opinions on mCRPC management

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.